Skip to main content
SpringerLink
Log in

Immunotherapy—another breakthrough in gastrointestinal malignancies

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Immunotherapy is a breakthrough in different tumor entities. Recently, immunotherapy became an important treatment modality in gastrointestinal (GI) malignancies. In GI malignancies, immunotherapy with or without chemotherapy or targeted agents is revolutionizing the treatment landscape and our daily clinical practice. In this review, we discuss the relevance of immunotherapy in GI malignancies and provide a perspective on promising upcoming treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. de Ruiter EJ, Mulder FJ, Koomen BM, et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol. 2021;34(6):1125–32. https://doi.org/10.1038/s41379-020-0644-7.

    Article  CAS  PubMed  Google Scholar 

  2. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD‑1 blockade. Science. 2017;357(6349):409–13. https://doi.org/10.1126/science.aan6733.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kato K, Sun J, Shah MA, et al. Pembrolizumab plus chemotherapy vs chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase III KEYNOTE-590 study. Ann Oncol. 2020;31(4):S1142–S215. https://doi.org/10.1016/j.annonc.2020.08.2298.

    Article  Google Scholar 

  4. Chau I, Doki Y, Ajani JA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the checkmate 648 study. J Clin Oncol. 2021;39(18):LBA4001–LBA4001.

    Google Scholar 

  5. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203. https://doi.org/10.1056/NEJMoa2032125.

    Article  CAS  PubMed  Google Scholar 

  6. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Moehler MH, Shitara K, Garrido M, et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649. J Clin Oncol. 2021;39(15):4002–4002.

    Article  Google Scholar 

  8. Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821–31. https://doi.org/10.1016/S1470-2045(20)30169-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rha SY, Lee C‑K, Kim H, et al. Targeting HER2 in combination with anti-PD‑1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: a multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC). J Clin Oncol. 2020;38(15):3081–3081.

    Article  Google Scholar 

  10. Janjigian YY, Kawazoe A, Yanez PE, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. J Clin Oncol. 2021;39(15):4013–4013.

    Article  Google Scholar 

  11. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

    Article  CAS  Google Scholar 

  12. Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–70.

    Article  Google Scholar 

  13. Llovet JM, Kudo M, Cheng A‑L, et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study. J Clin Oncol. 2019;37(15):TPS4152.

    Article  Google Scholar 

  14. André T, Shiu K‑K, Kim TW, et al. Pembrolizumab in microsatellite-instability—high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.

    Article  Google Scholar 

  15. Andre T, Shiu K‑K, Kim TW, et al. Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(15):3500–3500.

    Article  Google Scholar 

  16. Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus Ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9.

    Article  CAS  Google Scholar 

  17. Gomez-Roca C, Yanez E, Im S‑A, et al. LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—results from the colorectal cancer cohort. J Clin Oncol. 2021;39(3):94–94.

    Article  Google Scholar 

  18. Smyth EC, Gambardella V, Cervantes A, et al. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol. 2021;32(5):590–9. https://doi.org/10.1016/j.annonc.2021.02.004.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine II (Oncology, Hematology, Gastroenterology, Infectiology), Landeskrankenhaus Feldkirch, Carinagasse 47, 6800, Feldkirch, Austria

    Monika Lenzi &  Thomas Winder PhD

Authors
  1. Monika Lenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Winder PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Lenzi.

Ethics declarations

Conflict of interest

M. Lenzi and T. Winder declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lenzi, M., Winder, T. Immunotherapy—another breakthrough in gastrointestinal malignancies. memo 15, 20–25 (2022). https://doi.org/10.1007/s12254-021-00785-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-021-00785-3

Keywords

Search

Navigation